Pros on CNBC discussed Biogen after the Food and Drug Administration approved its Alzheimer’s drug.
You are here: Home / Biogen shares fall after Alzheimer’s drug approval. Here’s what the pros are saying
Market News and Views
Pros on CNBC discussed Biogen after the Food and Drug Administration approved its Alzheimer’s drug.